1353644-50-4

Basic information

• Product Name: 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane
• CAS NO: 1353644-50-4
• Molecular Weight: 265.783
• Mol File: 1353644-50-4.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane(1353644-50-4)
• EPA Substance Registry System: 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane(1353644-50-4)

Safety Data

• Hazardous Substances Data: 1353644-50-4(Hazardous Substances Data)

Usage

Description

1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is a complex organic compound characterized by its unique molecular structure. It features a cyclopropane ring with a phenyl group attached to one carbon, a diethylaminocarbonyl group on another, and a chloromethyl group on the third carbon. 1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is known for its potential applications in various industries due to its chemical properties.

Uses

Used in Pharmaceutical Industry:
1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific targeting and therapeutic properties.
Used in Chemical Research:
1-phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is also utilized in chemical research as a model for studying the reactivity and behavior of cyclopropane rings and their derivatives. It can provide insights into the mechanisms of various chemical reactions and help in the design of new synthetic pathways.
Used in Antidepressant Development:
1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is used as a precursor in the development of selective norepinephrine and serotonin reuptake inhibitors, such as Milnacipran. These drugs are approved for the management of fibromyalgia and can potentially be used to treat other conditions related to neurotransmitter imbalances.
Used in Impurity Analysis:
As an impurity of Milnacipran (M344600), 1-Phenyl-1-diethylaminocarbonyl-2-chloromethylcyclopropane is important in the quality control and regulatory processes of the pharmaceutical industry. Its analysis and control ensure the safety and efficacy of the final drug product.

Upstream product

• 140-29-4 phenylacetonitrile 
• 109-89-7 diethylamine 
• 63106-93-4 (1S,5R)-1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 
• 172015-99-5 (1 S,2 R)-N,N-diethyl-2-(hydroxymethyl)-1-phenylcyclopropane-carboxamide 
• 172016-06-7 (1R,2S)-1-phenyl-2-(hydroxymethyl)-N,N-diethylcyclopropanecarboxamide 

Relevant articles and documents

Preparation method of milnacipra hydrochloride intermediate

The invention provides a preparation method of an intermediate hydrochloride intermediate. Belong to chemical medicine preparation technical field. To the preparation method, the compound having the structure of the formula (II) is added into the methanol

Preparation method of levomilnacipran hydrochloride

The invention relates to the field of chemical medicines and organic synthesis and in particular relates to a preparation method of levomilnacipran hydrochloride. Aiming at solving the problems of anexisting method for preparing the levomilnacipran hydrochloride that the cost is relatively high or a generation process is relatively dangerous so that large-scale industrial production is limited, the preparation method is characterized by comprising the following steps: [1] enabling phenylacetonitrile and (R)-2-chloromethyl ethylene oxide to react under the action of sodium amide to obtain a compound 1; then carrying out hydrolysis cyclization on the compound 1 to obtain a compound 2; [2] enabling the compound 2 and thionyl chloride to react in alcohol, so as to obtain a compound 3; [3] enabling the compound 3 to be subjected to exchange reaction through introducing nitryl and amino, so as to obtain a compound 6; [4] reducing nitryl in the compound 6 and forming salt in situ to obtain the levomilnacipran hydrochloride. The preparation method provided by the invention is applicable to industrial production of the levomilnacipran hydrochloride.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain.